128 results about "Artificial tears" patented technology

An apparatus and system, and methods for using such apparatus and system, is provided for preserving the eye's natural and artificial tears. The apparatus comprises two soft, pliable eyecups, which each include and curved lens and contoured frame, connected by a soft, pliable bridge. The lenses are maintained within a pliable, and contoured frame that is designed and constructed to encircle the orbital bone of the eye sockets, creating a custom fit and effective seal over each eye. Attached to each frame is a gasket that further seals the apparatus over the eyes and provides additional comfort to the wearer. A contoured strap, which is attached to each frame, maintains the position of the apparatus on the wearer.

A system and method are provided for measuring the thickness of a tear film layer and the heights of tear menisci around upper and lower eyelids of an eye. A plurality of images are acquired between consecutive blinks the eye using optical coherence tomography (OCT). The images depict the tear film layer and tear menisci as distinct from the cornea of the eye. In an embodiment, a plurality of reflectivity profiles from an OCT image are aligned and averaged. The difference between a first peak and a second peak of the average reflectivity profile is measured to determine the thickness of the tear film layer. The heights of the upper meniscus and the lower meniscus can also be measured from the same OCT image. In an embodiment, thickness measurements from the plurality of OCT images are combined. The measurements can be used to diagnose tear disorders, analyze treatments of dry eye and evaluate artificial tears.

A formulation has been developed for treatment of the symptoms of dry eye which incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear and eyedrop as well as stabilize the eyedrop. The improved performance of the jojoba wax supplemented tear relieves irritation and discomfort as well as sharpens the blurred vision.

The present invention provides ophthalmic compositions, e.g. artificial tears, suitable for treating dry eye syndrome in a human or other mammal suffering there from, e.g. a dog or cat, which comprise a mixture of castor oil with another oil, e.g. a food oil, e.g. olive oil, sesame oil, corn oil etc.

A jojoba formulation has been developed for administration to the meibomian gland, for treatment of the symptoms of dry eye, and / or for drug delivery to the meibomian gland. The formulation incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear as well as stabilize the tear film. The jojoba wax tear relieves irritation and discomfort as well as sharpens the blurred vision. Jojoba, because of its close chemical and physical properties to meibomian gland secretions, is effective upon topical application to penetrate the lid margin to reach the gland tissues where it may exert a therapeutic effect with or without an adjunctive agent.

An aqueous artificial tear / rewetting drop solution is described. The solution may be utilized as both an artificial tear for persons wearing contact lenses and as a contact lens rewetting drop. The solution is based on the use of a citric acid / sodium citrate buffer system to prevent binding or other complexation between cationic antimicrobial preservatives and soft contact lenses, thereby making it possible to apply the solution directly to contact lenses while the lenses are being worn.

The use of bis-amines to enhance the antimicrobial activity of pharmaceutical compositions is described. The bis-amines are particularly useful for enhancing the antimicrobial activity of aqueous ophthalmic compositions, such as artificial tears or ocular lubricants, and solutions for disinfecting contact lenses.

The invention discloses an ophthalmologic external preparation, as well as a preparation method and an application thereof, belongs to the technical field of pharmaceuticals, and relates to a pharmaceutical active substance-ginsenoside which is prepared to form eye drops, oculentum, ophthalmologic gel, ophthalmologic external hydropathic compressing tissues and ophthalmologic external atomized liquid for treating dry eyes. The addition of the ginsenoside is 0.1-5.0 wt%. The ophthalmologic external preparation also is added with one or a plurality of pharmaceutical active substances which are selected from flos lonicerae, radix arnebiae, herba taraxaci, chrysanthemum and borneol. The pharmacodynamical and experimental research of the preparation shows that the ginsenoside has a function of increasing conjunctival goblet cells and effectively treating the dry eyes; and the preparation is safe and effective, is better than conventional single-thickening agent artificial tears and has significant popularization and application values.